Endogenous Adenosine 5'-Monophosphate, But Not Acetylcholine or Histamine, is Associated with Asthma Control, Quality of Life, and Exacerbations.
Fang, XM
Liu, Y
Wang, J
Zhang, X
Wang, L
Zhang, L
Zhang, HP
Liu, L
Huang, D
Liu, D
Deng, K
Luo, FM
Wan, HJ
Li, WM
Wang, G
Oliver, BG
- Publisher:
- SPRINGER
- Publication Type:
- Journal Article
- Citation:
- Lung, 2022, 200, (5), pp. 579-589
- Issue Date:
- 2022-10
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
s00408-022-00570-x.pdf | 1.26 MB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Fang, XM | |
dc.contributor.author | Liu, Y | |
dc.contributor.author | Wang, J | |
dc.contributor.author | Zhang, X | |
dc.contributor.author | Wang, L | |
dc.contributor.author | Zhang, L | |
dc.contributor.author | Zhang, HP | |
dc.contributor.author | Liu, L | |
dc.contributor.author | Huang, D | |
dc.contributor.author | Liu, D | |
dc.contributor.author | Deng, K | |
dc.contributor.author | Luo, FM | |
dc.contributor.author | Wan, HJ | |
dc.contributor.author | Li, WM | |
dc.contributor.author | Wang, G | |
dc.contributor.author | Oliver, BG | |
dc.date.accessioned | 2023-01-31T02:51:49Z | |
dc.date.available | 2022-09-05 | |
dc.date.available | 2023-01-31T02:51:49Z | |
dc.date.issued | 2022-10 | |
dc.identifier.citation | Lung, 2022, 200, (5), pp. 579-589 | |
dc.identifier.issn | 0341-2040 | |
dc.identifier.issn | 1432-1750 | |
dc.identifier.uri | http://hdl.handle.net/10453/165655 | |
dc.description.abstract | OBJECTIVE: Endogenous adenosine 5'-monophosphate (AMP), acetylcholine (ACh), and histamine (HA) are known to be important in bronchial contraction, but their clinical relevance to asthma is poorly understood. We aimed to quantify endogenous AMP, ACh, and HA in induced sputum samples and explore their relationships with asthma control and exacerbations. METHODS: 20 healthy subjects and 112 asthmatics underwent clinical assessment, sputum induction, and blood sampling. The level of asthma control was determined by the asthma control test (ACT) questionnaire. Asthma exacerbation was evaluated according to the criteria of the American Thoracic Society/European Respiratory Society. Levels of AMP, ACh, and HA in sputum were measured by liquid chromatography coupled to tandem mass spectrometry. IL-β, IL-4, IL-5, IL-6, IL-8, IL-13, IL-17A, TNF-α, IFN-γ, and macrophage-derived chemokine (MDC) were also measured. RESULTS: Compared to healthy controls, asthmatics had higher levels of HA, lower levels of ACh, and similar levels of AMP in induced sputum samples. Compared to controlled asthma (n = 54), uncontrolled asthma (n = 58) showed higher AMP levels (P = 0.002), but similar HA and ACh levels. AMP was negatively correlated with ACT scores (r = - 0.348) and asthma quality of life questionnaire scores (r = - 0.188) and positively correlated with blood monocytes percentage (r = 0.195), sputum MDC (r = 0.214), and IL-6 levels (r = 0.196). Furthermore, AMP was associated with an increased risk of exacerbations in the preceding year. CONCLUSION: Endogenous AMP, but not ACh or HA, was associated with asthma control, quality of life, and exacerbations in the previous year, which indicates that AMP could be a clinically useful biomarker of asthma. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | SPRINGER | |
dc.relation.ispartof | Lung | |
dc.relation.isbasedon | 10.1007/s00408-022-00570-x | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | 1102 Cardiorespiratory Medicine and Haematology | |
dc.subject.classification | Respiratory System | |
dc.subject.mesh | Acetylcholine | |
dc.subject.mesh | Adenosine | |
dc.subject.mesh | Adenosine Monophosphate | |
dc.subject.mesh | Asthma | |
dc.subject.mesh | Biomarkers | |
dc.subject.mesh | Chemokine CCL22 | |
dc.subject.mesh | Histamine | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Interleukin-13 | |
dc.subject.mesh | Interleukin-17 | |
dc.subject.mesh | Interleukin-4 | |
dc.subject.mesh | Interleukin-5 | |
dc.subject.mesh | Interleukin-6 | |
dc.subject.mesh | Interleukin-8 | |
dc.subject.mesh | Quality Control | |
dc.subject.mesh | Quality of Life | |
dc.subject.mesh | Sputum | |
dc.subject.mesh | Tumor Necrosis Factor-alpha | |
dc.subject.mesh | Sputum | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Asthma | |
dc.subject.mesh | Acetylcholine | |
dc.subject.mesh | Histamine | |
dc.subject.mesh | Tumor Necrosis Factor-alpha | |
dc.subject.mesh | Adenosine | |
dc.subject.mesh | Adenosine Monophosphate | |
dc.subject.mesh | Interleukin-8 | |
dc.subject.mesh | Interleukin-4 | |
dc.subject.mesh | Interleukin-5 | |
dc.subject.mesh | Interleukin-6 | |
dc.subject.mesh | Interleukin-13 | |
dc.subject.mesh | Interleukin-17 | |
dc.subject.mesh | Quality of Life | |
dc.subject.mesh | Quality Control | |
dc.subject.mesh | Chemokine CCL22 | |
dc.subject.mesh | Biomarkers | |
dc.title | Endogenous Adenosine 5'-Monophosphate, But Not Acetylcholine or Histamine, is Associated with Asthma Control, Quality of Life, and Exacerbations. | |
dc.type | Journal Article | |
utslib.citation.volume | 200 | |
utslib.location.activity | United States | |
utslib.for | 1102 Cardiorespiratory Medicine and Haematology | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science | |
pubs.organisational-group | /University of Technology Sydney/Strength - CHT - Health Technologies | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science/School of Life Sciences | |
pubs.organisational-group | /University of Technology Sydney/Centre for Health Technologies (CHT) | |
utslib.copyright.status | closed_access | * |
dc.date.updated | 2023-01-31T02:51:47Z | |
pubs.issue | 5 | |
pubs.publication-status | Published | |
pubs.volume | 200 | |
utslib.citation.issue | 5 |
Abstract:
OBJECTIVE: Endogenous adenosine 5'-monophosphate (AMP), acetylcholine (ACh), and histamine (HA) are known to be important in bronchial contraction, but their clinical relevance to asthma is poorly understood. We aimed to quantify endogenous AMP, ACh, and HA in induced sputum samples and explore their relationships with asthma control and exacerbations. METHODS: 20 healthy subjects and 112 asthmatics underwent clinical assessment, sputum induction, and blood sampling. The level of asthma control was determined by the asthma control test (ACT) questionnaire. Asthma exacerbation was evaluated according to the criteria of the American Thoracic Society/European Respiratory Society. Levels of AMP, ACh, and HA in sputum were measured by liquid chromatography coupled to tandem mass spectrometry. IL-β, IL-4, IL-5, IL-6, IL-8, IL-13, IL-17A, TNF-α, IFN-γ, and macrophage-derived chemokine (MDC) were also measured. RESULTS: Compared to healthy controls, asthmatics had higher levels of HA, lower levels of ACh, and similar levels of AMP in induced sputum samples. Compared to controlled asthma (n = 54), uncontrolled asthma (n = 58) showed higher AMP levels (P = 0.002), but similar HA and ACh levels. AMP was negatively correlated with ACT scores (r = - 0.348) and asthma quality of life questionnaire scores (r = - 0.188) and positively correlated with blood monocytes percentage (r = 0.195), sputum MDC (r = 0.214), and IL-6 levels (r = 0.196). Furthermore, AMP was associated with an increased risk of exacerbations in the preceding year. CONCLUSION: Endogenous AMP, but not ACh or HA, was associated with asthma control, quality of life, and exacerbations in the previous year, which indicates that AMP could be a clinically useful biomarker of asthma.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph